The compelling case for anti-CD3 in type 1 diabetes
Diabetes
.
2013 Nov;62(11):3656-7.
doi: 10.2337/db13-1157.
Author
Jay S Skyler
1
Affiliation
1
Diabetes Research Institute, University of Miami, Miami, Florida.
PMID:
24158991
PMCID:
PMC3806623
DOI:
10.2337/db13-1157
No abstract available
Publication types
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use*
C-Peptide / metabolism*
Diabetes Mellitus, Type 1 / drug therapy*
Female
Humans
Male
Substances
Antibodies, Monoclonal, Humanized
C-Peptide
teplizumab